Related Experiment Videos
Prophylaxis with factor concentrates in preventing hemophilic arthropathy
P Petrini1, N Lindvall, N Egberg
1Department of Pediatrics, Karolinska Hospital, Stockholm, Sweden.
The American Journal of Pediatric Hematology/Oncology
|January 1, 1991
Summary
Early prophylactic treatment for severe hemophilia A is crucial. Starting therapy between ages 1-2 years significantly reduces ankle joint bleeding and damage compared to later initiation.
Area of Science:
- Pediatric Hematology
- Orthopedic Complications in Hemophilia
- Prophylactic Therapy Efficacy
Background:
- Severe hemophilia A poses a significant risk of recurrent joint bleeding (hemarthroses), particularly in ankles.
- Prophylactic substitution therapy aims to prevent bleeding episodes and long-term joint damage in children with hemophilia A.
- The optimal timing for initiating prophylactic treatment remains a critical factor in managing hemophilic arthropathy.
Purpose of the Study:
- To compare the long-term outcomes of prophylactic therapy initiated at different ages in children with severe hemophilia A.
- To assess the impact of early versus later initiation of Factor VIII concentrate prophylaxis on hemarthroses and radiological joint changes.
Main Methods:
- Longitudinal study comparing two groups of seven children with severe hemophilia A.
- Group I: Prophylactic therapy initiated at a mean age of 5 years, assessed at two time points (ages 6-12 and 16-22).
- Group II: Prophylactic therapy initiated at a mean age of 3 years, assessed between ages 5-12.
Main Results:
- Children initiating therapy later (Group I) experienced significantly more ankle hemarthroses (>20 episodes) compared to early starters (Group II, one child).
- Radiological ankle changes were prevalent in 5/7 children in Group I versus 1/7 in Group II at initial assessment.
- Progression of radiological changes was observed in 8/10 ankles of Group I children upon reinvestigation.
Conclusions:
- Early initiation of regular prophylactic therapy, ideally between 1-2 years of age, is essential to prevent ankle joint damage in severe hemophilia A.
- Effective prophylactic regimens involve frequent administration of modern Factor VIII concentrates (e.g., 3,000 U/kg/year), allowing children to participate in sports.
- Education on recognizing ankle bleeding and consistent adherence to therapy are vital for minimizing hemarthroses and preserving joint health.